Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation
Background: In the treatment of advanced urothelial (aUC) and renal cell carcinoma (aRCC), biomarkers such as PD-1 and PD-L1 are not robust prognostic markers for immunotherapy (IO) response. Previously, a significant association between IO and a change in splenic volume (SV) was described for sever...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/9/2482 |
| _version_ | 1797581152785006592 |
|---|---|
| author | Gregor Duwe Lukas Müller Christian Ruckes Nikita Dhruva Fischer Lisa Johanna Frey Jan Hendrik Börner Niklas Rölz Maximilian Haack Peter Sparwasser Tobias Jorg Christopher C. M. Neumann Igor Tsaur Thomas Höfner Axel Haferkamp Felix Hahn Rene Mager Maximilian Peter Brandt |
| author_facet | Gregor Duwe Lukas Müller Christian Ruckes Nikita Dhruva Fischer Lisa Johanna Frey Jan Hendrik Börner Niklas Rölz Maximilian Haack Peter Sparwasser Tobias Jorg Christopher C. M. Neumann Igor Tsaur Thomas Höfner Axel Haferkamp Felix Hahn Rene Mager Maximilian Peter Brandt |
| author_sort | Gregor Duwe |
| collection | DOAJ |
| description | Background: In the treatment of advanced urothelial (aUC) and renal cell carcinoma (aRCC), biomarkers such as PD-1 and PD-L1 are not robust prognostic markers for immunotherapy (IO) response. Previously, a significant association between IO and a change in splenic volume (SV) was described for several tumour entities. To the best of our knowledge, this study presents the first correlation of SV to IO in aUC and aRCC. Methods: All patients with aUC (05/2017–10/2021) and aRCC (01/2012–05/2022) treated with IO at our academic centre were included. SV was measured at baseline, 3 and 9 months after initiation of IO using an in-house developed convolutional neural network-based spleen segmentation method. Uni- and multivariate Cox regression models for overall survival (OS) and progression-free survival (PFS) were used. Results: In total, 35 patients with aUC and 30 patients with aRCC were included in the analysis. Lower SV at the three-month follow-up was significantly associated with improved OS in the aRCC group. Conclusions: We describe a new, innovative artificial intelligence-based approach of a radiological surrogate marker for IO response in aUC and aRCC which presents a promising new predictive imaging marker. The data presented implicate improved OS with lower follow-up SV in patients with aRCC. |
| first_indexed | 2024-03-10T23:00:06Z |
| format | Article |
| id | doaj.art-36404aee65c6482bbef2b7c498f84982 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T23:00:06Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-36404aee65c6482bbef2b7c498f849822023-11-19T09:41:57ZengMDPI AGBiomedicines2227-90592023-09-01119248210.3390/biomedicines11092482Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic SegmentationGregor Duwe0Lukas Müller1Christian Ruckes2Nikita Dhruva Fischer3Lisa Johanna Frey4Jan Hendrik Börner5Niklas Rölz6Maximilian Haack7Peter Sparwasser8Tobias Jorg9Christopher C. M. Neumann10Igor Tsaur11Thomas Höfner12Axel Haferkamp13Felix Hahn14Rene Mager15Maximilian Peter Brandt16Department of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Diagnostic and Interventional Radiology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyInterdisciplinary Center for Clinical Trials Mainz, University Medical Center, Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Diagnostic and Interventional Radiology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, 10117 Berlin, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Diagnostic and Interventional Radiology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyDepartment of Urology and Pediatric Urology, University Medical Center, Johannes-Gutenberg University Mainz, Langenbeckstrasse 1, 55131 Mainz, GermanyBackground: In the treatment of advanced urothelial (aUC) and renal cell carcinoma (aRCC), biomarkers such as PD-1 and PD-L1 are not robust prognostic markers for immunotherapy (IO) response. Previously, a significant association between IO and a change in splenic volume (SV) was described for several tumour entities. To the best of our knowledge, this study presents the first correlation of SV to IO in aUC and aRCC. Methods: All patients with aUC (05/2017–10/2021) and aRCC (01/2012–05/2022) treated with IO at our academic centre were included. SV was measured at baseline, 3 and 9 months after initiation of IO using an in-house developed convolutional neural network-based spleen segmentation method. Uni- and multivariate Cox regression models for overall survival (OS) and progression-free survival (PFS) were used. Results: In total, 35 patients with aUC and 30 patients with aRCC were included in the analysis. Lower SV at the three-month follow-up was significantly associated with improved OS in the aRCC group. Conclusions: We describe a new, innovative artificial intelligence-based approach of a radiological surrogate marker for IO response in aUC and aRCC which presents a promising new predictive imaging marker. The data presented implicate improved OS with lower follow-up SV in patients with aRCC.https://www.mdpi.com/2227-9059/11/9/2482advanced urothelial carcinomaadvanced renal cell carcinomaimmunotherapyimmune checkpoint inhibitorprognostic markerpredictive marker |
| spellingShingle | Gregor Duwe Lukas Müller Christian Ruckes Nikita Dhruva Fischer Lisa Johanna Frey Jan Hendrik Börner Niklas Rölz Maximilian Haack Peter Sparwasser Tobias Jorg Christopher C. M. Neumann Igor Tsaur Thomas Höfner Axel Haferkamp Felix Hahn Rene Mager Maximilian Peter Brandt Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation Biomedicines advanced urothelial carcinoma advanced renal cell carcinoma immunotherapy immune checkpoint inhibitor prognostic marker predictive marker |
| title | Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation |
| title_full | Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation |
| title_fullStr | Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation |
| title_full_unstemmed | Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation |
| title_short | Change in Splenic Volume as a Surrogate Marker for Immunotherapy Response in Patients with Advanced Urothelial and Renal Cell Carcinoma—Evaluation of a Novel Approach of Fully Automated Artificial Intelligence Based Splenic Segmentation |
| title_sort | change in splenic volume as a surrogate marker for immunotherapy response in patients with advanced urothelial and renal cell carcinoma evaluation of a novel approach of fully automated artificial intelligence based splenic segmentation |
| topic | advanced urothelial carcinoma advanced renal cell carcinoma immunotherapy immune checkpoint inhibitor prognostic marker predictive marker |
| url | https://www.mdpi.com/2227-9059/11/9/2482 |
| work_keys_str_mv | AT gregorduwe changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT lukasmuller changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT christianruckes changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT nikitadhruvafischer changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT lisajohannafrey changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT janhendrikborner changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT niklasrolz changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT maximilianhaack changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT petersparwasser changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT tobiasjorg changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT christophercmneumann changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT igortsaur changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT thomashofner changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT axelhaferkamp changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT felixhahn changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT renemager changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation AT maximilianpeterbrandt changeinsplenicvolumeasasurrogatemarkerforimmunotherapyresponseinpatientswithadvancedurothelialandrenalcellcarcinomaevaluationofanovelapproachoffullyautomatedartificialintelligencebasedsplenicsegmentation |